tbuckley/cabot-search huggingface dataset:
Comprehensive genomic profiling of neuroendocrine carcinoma of the prostate.
Authors: Philip J. Stephens, Laurie M Gay, Siraj Mahamed Ali, Jean H. Hoffman-Censits, Julia Andrea Elvin, Jo-Anne Vergilio, James Suh, Badar Mian, Hugh A.G. Fisher, Tipu Nazeer, Vincent A. Miller, Sumanta K. Pal, Jeffrey S. Ross
Journal: Journal of Clinical Oncology (2016)

5027 Background: Neuroendocrine carcinoma of the prostate (NCAP) is an aggressive high grade malignancy that often presents as metastatic disease. Current treatments of this tumor have only modest benefit leading investigators to query whether comprehensive genomic profiling (CGP) would have potential to discover novel targets of therapy. Methods: DNA was extracted from 40 microns of FFPE sections from 37 consecutive cases of relapsed/metastatic NCAP. CGP was performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of 583X for up to 315 cancer-related genes plus 37 introns from 14 genes frequently rearranged in cancer. Genomic alterations (GA) included base substitutions (SUB), INDELs, copy number alterations (CNA) and fusions/rearrangements. Clinically relevant GA (CRGA) were defined as GA linked to drugs on the market or under evaluation in mechanism driven clinical trials. Results: The mean age of the men in this study was 65.1 years (range 43 to 83 years). All (100%) cases were positive for neuroendocrine markers on immunohistochemical staining and were Stage IV at the time of CGP. Samples used for sequencing were obtained from the primary tumor in 9 (24%) of NCAP and from metastatic sites in 28 (76%) of NCAP (12 liver, 6 LN, 2 each from bladder, pelvis and soft tissue, and 1 each from rectum, bone, urethra and ureter. There were 213 total GA (5.8 GA/sample) and 47 CRGA (1.3 CRGA/sample). The most frequent GA were non-CRGA mutations in TP53 (68%) and RB1 (51%). TMPRSS:ERG fusions were identified in 32% of cases whereas AR was altered in 8% (1 mutation and 2 amplifications). The most frequent CRGA involved PTEN (32%), BRCA2 (14%), FGFR1 (5%), PIK3CA (5%) and AKT2 (3%). No alterations in BRAF were identified. Clinical responses to MTOR inhibitors in patients with MTOR pathway alterations will be presented. Conclusions: NCAP has distinctive genomic alterations from classic acinar CAP including reduced frequencies of alterations in TMPRSS:ERG and AR and frequent RB1 mutations. Multiple alterations in the MTOR pathway identified in this infrequent tumor type suggest that these patients may be candidates for MTOR inhibitors and other targeted therapies.
British Journal of Haematology, Oxford
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CANCER OF THE RECTUM
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 316: Effect of Different Substrates on Functional Performance and Kinase Activation During Reperfusion After Ischemia in Hearts from Obese Insulin Resistant Rats
Authors: Amanda Lochner, Wen-Jun Fan, Barbara Huisamen
Journal: Circulation Research (2012)

Insulin resistance decreases glucose uptake, alters lipid metabolism and impairs PKB-dependent signaling in its target tissues. In view of the myocardial dependence on glycolysis during energy deficiency, insulin resistance may exacerbate the harmful effects of ischaemia. We hypothesize that obesity-induced insulin resistance affects functional recovery and activation of PKB, JNK, ERK and PTEN during early reperfusion. Methods: Insulin resistance was induced by feeding rats a high calorie diet for 16 weeks. Hearts from diet rats (D) and age-matched controls (C) were subjected to (i) 15 min global ischaemia and different reperfusion times for Western blot and measurement of functional recovery, or (ii) 35 min regional ischaemia and 2 hours reperfusion for infarct size determination (IS) using tetrazolium. Substrates were glucose (G) (10mM) or glucose (10mM) plus fatty acid (FA) (1.2mM palmitate /3%BSA) (G+FA). N=4-8/group. Results: Regardless of the substrate, functional recovery during reperfusion of hearts from D was higher than those of C (% recovery of total work: D+G/C+G, 69.1±3.4/50.7±4.5, D+G+FA/C+G+FA: 105.4±3.6/92.7±3.9), associated with a reduction in IS (D+G/C+G 29.7±2.8/43.5±2.5, p&lt;0.05; D+G+FA/C+G+FA 26.7±3.2/36.6±4, p&lt;0.05). When perfused with glucose hearts from D showed increased activation of PKB and JNK at different times during reperfusion (D+G/C+G: 10 min PKBs473, 1.41±0.11/1.00±0.06; JNKp54, 1.80±0.15/1.00±0.13; JNKp46, 1.59±0.11/1.00±0.08). Addition of FA caused further activation of the kinases (e.g. D+G+FA/D+G: 5 min ERKp44, 1.54±0.11/1.00±0.11, ERKp42, 1.46±0.13/1.00±0.07; 10 min ERKp44, 1.83±0.19/1.00±0.05, ERKp42, 1.27±0.10/1.00±0.05; 30 min PKBs473, 2.91±0.35/1.00±0.09) and inhibition of PTEN (1.79±0.11/1.00±0.10). Conclusion: Contrary to expectations, hearts from D rats showed an increased tolerance to ischaemia/reperfusion (I/R) injury which was further improved by fatty acids in the perfusate. The pattern of PKB, JNK, ERK and PTEN phosphorylation during reperfusion is substrate dependent and significantly higher in hearts from D rats. With glucose as substrate activation of PKB and JNK during reperfusion was higher in hearts from D rats while FA further improved activation of ERK and PKB.
A critical evaluation of the Mefar&lt;SUP&gt;TM&lt;/SUP&gt; dosimeter
Authors: R.J. Ward, P. Liakakos, R.F. Leonard, D.W. Reid, D.P. Johns, E.H. Walters
Journal: European Respiratory Journal (1999)

The aim of this study was to describe the lesions of pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma observed by means of computed tomography (CT) and to determine the value of CT in the management of this disease. Sixty six CT scans were performed in 13 consecutive cases of histologically proven pulmonary MALT lymphoma at the time of diagnosis (n=13) or periodically (n=53). They were reviewed separately with chest radiographs by consensus between two observers. Pulmonary abnormalities were described and compared to histopathological findings on surgical specimens from seven patients. At the time of diagnosis, elementary lesions observed by means of CT consisted of nodular areas of attenuation (12 of 13), linear areas of attenuation (eight of 13) and consolidations (six of 13). All these lesions were centred on airways that appeared dilated in seven cases and were more often bilateral and multiple on CT than on the chest radiographs. CT abnormalities correlated with gross pathological appearance and were related to a lymphomatous infiltration with a peribronchovascular distribution. Pathological examination also confirmed the presence of dilated airways within lymphomatous lesions and showed that the bronchial wall was respected. During follow-up, in patients on chemotherapy, response, relapse or progression were easily identified by means of plain radiography. In the initial evaluation, computed tomography contributed to the choice of therapeutic strategy, avoiding unnecessary surgical resection in one-third of patients. By contrast, it is unclear whether computed tomography is useful for post-treatment follow-up of mucosa-associated lymphoid tissue.
The Centennial of the Stethoscope
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers
Authors: Terence K. Lee, Saravana R.K. Murthy, Niamh X. Cawley, Savita Dhanvantari, Stephen M. Hewitt, Hong Lou, Tracy Lau, Stephanie Ma, Thanh Huynh, Robert A. Wesley, Irene O. Ng, Karel Pacak, Ronnie T. Poon, Y. Peng Loh
Journal: Journal of Clinical Investigation (2019)
Phase I study of procaspase activating compound-1 (PAC-1) for treatment of advanced malignancies.
Authors: Oana C. Danciu, Martin Kelly Nicholas, Matthias Holdhoff, Richard A. Peterson, Theodore M Tarasow, Paul J. Hergenrother, Arkadiusz Z. Dudek
Journal: Journal of Clinical Oncology (2018)

TPS2621 Background: Dysregulation in apoptotic pathways is a hallmark feature of cancer, offering opportunities for pharmacologic intervention in its treatment. Caspases, a family of proteases, play several roles in apoptosis. Caspase-3 catalyzes the intra-cellular proteolysis that characterizes part of the apoptotic process. Caspase-3 levels are low in many tumors including: glioblastoma; breast, colon, lung, and liver cancers: lymphoma: neuroblastoma; and melanoma. In contrast, procaspase-3, the precursor of caspase-3 is elevated in these tumors. We describe a phase I study of PAC-1, a drug that catalyzes the conversion of procaspase -3 to caspase-3. It induces apoptosis in tumor cell lines in vitro. In vivo activity has also been shown, when combined with alkylating chemotherapy, in rodent glioma models and in canines diagnosed with malignant glioma. Methods: This Phase I dose escalation study has two components: the first (C1) to determine the maximum tolerated dose (MTD) of PAC-1 in advanced malignancies; the second (C2) to determine the MTD of PAC-1 when combined with temozolomide (TMZ) in patients with recurrent anaplastic astrocytoma (AA) or glioblastoma (GBM). A modified Fibonacci 3 + 3 design is used, expanding to nine subjects at the MTD level in each component. PAC-1 pharmacokinetics is assessed in all subjects during the first cycle. Secondary objectives include pharmacodynamics and correlations of PAC-1 activity with procaspase-3 expression in tumor tissue. Neurologic toxicity is closely monitored throughout the study. Inclusion criteria: diagnoses of advanced malignancies (C1) and recurrent AA or GBM (C2), ECOG PS 0-2, adequate organ function. Exclusion criteria: prior cytotoxic therapy in the last 3-6 weeks (varying with drug class) or uncontrolled chronic illness. Administration and design: For C1, PAC-1 (orally administered) is dosed at 75-1,000 mg daily on days 1-21 of each 28 day cycle. For C 2, the first PAC-1 dose is 375 mg daily with potential for escalation to 1,000 mg daily. TMZ, PO, is dosed at 150 mg/m2 daily, days 8-12, of each cycle. Enrollment to date for C1 is 27, (dose level 6); and for C2 is 4 (dose level 1). The study is open to accrual. Clinical trial information: NCT02355535.
Yeast-Recombinant Hepatitis B Vaccine
Authors: Cladd E. Stevens
Journal: JAMA (1987)

A yeast-recombinant hepatitis B vaccine was licensed recently by the Food and Drug Administration and is now available. To assess the efficacy of the yeast-recombinant vaccine, we administered the vaccine in combination with hepatitis B immune globulin to high-risk newborns. If infants whose mothers were positive for both hepatitis B surface antigen and the e antigen receive no immunoprophylaxis, 70% to 90% become infected with the virus, and almost all become chronic carriers. Among infants in this study who received hepatitis B immune globulin at birth and three 5-μg doses of yeast-recombinant hepatitis B vaccine, only 4.8% became chronic carriers, a better than 90% level of protection and a rate that is comparable with that seen with immune globulin and plasmaderived hepatitis B vaccine. These data suggest that, in this high-risk setting, the yeast-recombinant vaccine is as effective as the plasma-derived vaccine in preventing hepatitis B virus infection and the chronic carrier state. (<i>JAMA</i>1987;257:2612-2616)
Changes in the Cerebrum Associated with Experimental Obstructive Hydrocephalus
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Canadian Journal of Surgery, Toronto
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risk assessment of clinically significant portal hypertension by means of hepatosplenic volumetry in compensated cirrhosis
Authors: Mario Romero Cristóbal, Ana Clemente, Enrique Ramon Botella, Olga Ortega, Elena Velilla, Ana M Matilla, Laura Marquez, Maria Magdalena Salcedo, Sonia Alonso, Maria Vega Catalina, Ainhoa Fernandez, Fernando Diaz Fontela, Luis Ibañez, Diego Rincón, Rafael Bañares
Journal: Journal of Hepatology (2020)
Leukemia
Authors: M. M. Wintrobe
Journal: JAMA (1964)

So much has been written about leukemia that it is useful to have a volume of almost 600 pages, published in 1964, which assembles many of the accumulated publications. The second edition of the monograph by Dameshek and Gunz is 40% longer than the first. Although the material in many places is the same word for word as in the first edition, supplementary paragraphs have been added where appropriate and elsewhere new facts or interpretations have replaced what had been written before. Some 1,000 new references have been added, attesting to the degree of activity in this field. Unfortunately, some important papers have been omitted. Furthermore, there are many errors in the numbering of references, especially in Chapter 10, The illustrations of the former edition have been retained and a few new ones have been added. This monograph is comprehensive and will serve as a good source of information. The
Data Errors in Table 3 and Figure 1
Authors: John Ioannidis
Journal: JAMA (2020)

Victor A. van de Graaf, MD; Julia C. A. Noorduyn, MSc; Nienke W. Willigenburg, PhD; Ise K. Butter, MSc; Arthur de Gast, MD, PhD; Ben W. Mol, MD, PhD; Daniel B. F. Saris, MD, PhD; Jos W. R. Twisk, PhD; Rudolf W. Poolman, MD, PhD; for the ESCAPE Research Group
Women’s Health
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Surgical Therapy for Coronary Disease: Randomized and Observational Studies
Authors: David H. Mark
Journal: JAMA (1990)

<h3>To the Editor.—</h3> As Califf et al<sup>1</sup>mention in their discussion, the results of all observational studies must be interpreted cautiously because of potential selection bias. Statistical adjustment is a well-established method of attempting to control for selection bias. However, the choice of which factors to include in this adjustment are critical. As the authors state, although there are differences between patients treated medically and those treated surgically, there is a large overlap between the two groups in their baseline characteristics. This suggests two possibilities: either there are additional criteria, known by physicians, used to select either medical or surgical treatment, or, within this overlap group, selection is somehow haphazard or random. Since the latter seems unlikely, it is almost certain that additional undefined factors are used to select treatment. What the authors have done is carefully to adjust for factors associated with the prognosis of ischemic heart
WASHINGTON NEWS
Journal: JAMA (1967)

<h3>Medicare Testimony—</h3> The US Chamber of Commerce told the House Ways and Means Committee that the proposed 15% increase in Social Security cash benefits is too high, and that extension of Medicare to the disabled should be deferred "until adequate cost experience has been obtained." Both proposals are included in the Administration's Medicare bill, now being considered by the committee. The Chamber also opposed increasing the taxable wage base, favored limitations on the Title 19 program, and opposed the proposal to tax Social Security cash benefits. Speaking for the Chamber was Henry H. Chase, an official of the Humble Oil and Refining Co. "We seriously question the advisability and prudence of piling further heavy tax costs on top of the already high and rising tax requirements for Social Security," he said. "No one knows whether today's workers or the young workers of tomorrow are willing to support the full cost
Obstetrics and Gynecology
Authors: Edward C. Hill
Journal: JAMA (1987)

The ethics of human reproduction were brought sharply into focus this year by the Vatican's pronouncement that procreation of human life outside the body is "morally illicit." Also censured were artificial insemination, attempts at sex preselection, and surrogate motherhood (<i>San Francisco Chronicle</i>, March 11, 1987, pp 1, 8). Already, calls for legislative control of these activities have been heard. During the past decade, overwhelming advances in medical technology and the ethical issues involved in their use or nonuse have touched every field of medicine. Because many of these issues are related to the processes of human reproduction, they have had a profound effect on obstetrics and gynecology. Moreover, being social issues as well, they are the concern of everyone. Ever since the Supreme Court's landmark decision in 1973, moral and ethical questions of legalized abortion have haunted the nation. The debate rages on with prolife and prochoice advocates maintaining dogmatic positions,